We investigated the means by which drug resistance emerges among drug-susceptible Mycobacterium tuberculosis strains during antituberculosis therapy. Patients who experienced failure of treatment for active pulmonary tuberculosis, who initially received diagnoses of infection with drug-susceptible M. tuberculosis, and who had had at least 3 isolates tested for drug susceptibility were selected from a 6-year period in the Estonian National Reference Laboratory archive. Eleven patients from whom 35 sequential isolates of M. tuberculosis had been obtained were recruited into the study. Their clinical data and treatment charts were analyzed and correlated with drug-susceptibility patterns and IS6110 restriction fragment-length polymorphism (RFLP) profiles. Six patients excreted isogenic drug-susceptible M. tuberculosis strains, whereas, in the other 5 patients, the isolated strain shifted from a susceptible to a resistant phenotype. In all cases, this shift correlated to a shift in RFLP pattern, which showed reinfection with a new strain. Exogenous reinfection with drug-resistant M. tuberculosis may be misinterpreted as the emergence of drug resistance if molecular testing techniques are not used.
important mechanism by which M. tuberculosis adapts to host conditions when the host is receiving antimicrobial treatment. M. tuberculosis strains resistant to anti-TB drugs were found in all 58 geographic sites studied by the World Health Organization (WHO) between 1996 and 1999. The median prevalence of multidrug resistance among new cases of TB was 1.0%, but the prevalence in Estonia, one of the former Soviet republics, was much higher (14.1%) [4] . The highly irregular use of anti-TB treatment in Estonia, which does not correspond to the WHO's global treatment strategy, has been associated with high rates of multidrug-resistant (MDR) M. tuberculosis (i.e., M. tuberculosis that is resistant to at least isoniazid and rifampin) [4] [5] [6] [7] [8] [9] .
However, the role of inappropriate chemotherapy in failure to cure TB has, to our knowledge, not yet been proved by direct studies that assess the emergence of drug resistance during therapy for infection with drugsusceptible M. tuberculosis. Molecular testing methods could provide good tools [10] [11] [12] for investigating whether persistent TB is caused by genotypically isogenic strains.
The well-standardized and most widely applied molecular method for the study of M. tuberculosis complex isolates is IS6110 restriction fragment-length polymorphism (RFLP) typing [13] [14] [15] . Likewise, for distinguishing between strains of M. tuberculosis, spoligotyping [16] has been successfully applied in addition to IS6110 RFLP typing. Regardless of the molecular techniques and genetic markers available, few investigators have focused specifically on the simultaneous use of bacteriological, molecular/genetic, and clinical investigation methods to study the relationship between the quality of treatment and the development of resistance [17] .
To investigate the means by which drug resistance evolves among drug-susceptible M. tuberculosis strains during anti-TB treatment, a retrospective case series including patients with TB who had experienced failure of treatment for active pulmonary TB and who initially had received diagnoses of infection with drug-susceptible M. tuberculosis were selected from the Estonian National Reference Laboratory (ENRL) archive for our study. The IS6110 RFLP assay and spoligotyping were used, and the results were correlated with drugsusceptibility test results and treatment regimen and sociodemographic data.
PATIENTS, MATERIALS, AND METHODS

Patients.
From January 1994 through December 1999, 1037 patients in Tartu, Estonia, with culture-confirmed pulmonary TB were identified by the ENRL. During the 6-year period, 194 sequential isolates from 86 patients were tested for drug susceptibility. In that study, the following inclusion criteria were set for the patients: initial diagnosis of pulmonary infection with drug-susceptible M. tuberculosis, testing of at least 3 sequential isolates for drug susceptibility, and an interval of у2 months between testing of the first and second or the second and third isolates. Thirty-one patients had testing of at least 3 serial isolates for drug susceptibility. For 27 of those patients, the interval between testing of the first and second or second and third isolates was у2 months; the first isolate from 14 of the 27 patients was susceptible to the drug tested. The first isolate from 2 of those 14 patients was not available for additional (molecular) testing, and for 1 patient, 2 sequential isolates were not genotyped. Therefore, 11 (78.6%) of 14 patients and 35 M. tuberculosis isolates were included for further analyses (table 1, figure 1) .
Clinical data. The WHO-recommended strategy of TB control, which includes directly observed treatment and short-course chemotherapy, was applied in Estonia only after 1997. To document the regularity (e.g., use of a standard treatment regimen and dosages and level of patient compliance) versus irregularity of the anti-TB treatment applied, we searched patient treatment charts and outpatient cards for the following clinical data: duration of the current TB episode, duration of each course of treatment and total treatment duration, conditions under which treatment was administered (i.e., hospital, ambulatory setting, direct observation), number and length of treatment interruptions, and the drugs included in each regimen. Also, the clinical outcome of the treatment was recorded. In addition, some unfavorable sociodemographic factors-unemployment, alcohol abuse, and prior imprisonment-were used for analyses.
M. tuberculosis isolates. All available samples that we analyzed were kept frozen at Ϫ70ЊC before additional testing. Clinical isolates were identified as M. tuberculosis by use of a DNA probe (ACCUProbe; GenProbe). Isolates were tested for susceptibility to rifampin (breakpoint, 2.0 mg/mL), isoniazid (breakpoint, 0.1 mg/mL), streptomycin (breakpoint, 6 mg/mL), and ethambutol (breakpoint, 7.5 mg/mL) by the Bactec radiometric method (Becton Dickinson Diagnostic Instrument Systems). Resistance was judged by comparison of the change in the growth index of the control with that of the test drugs, as recommended by the manufacturer [18] .
Molecular techniques. IS6110 RFLP and spoligotyping were used to assess the stability of serial isolates. For IS6110 RFLP, M. tuberculosis isolates were subcultured onto Löwen-stein-Jensen slopes at 37ЊC for a minimum of 4 weeks before DNA extraction. Chromosomal DNA was prepared by chloroform-isoamyl alcohol DNA extraction, and 4.5 mg of DNA from each isolate was restricted with PvuII. Separation of PvuIIrestricted DNA by electrophoresis, Southern blot hybridization with a 245-bp PCR probe that recognized the right side of the restricted IS6110, and chemiluminescence detection was performed according to the standard method recommended for the DNA fingerprinting of M. tuberculosis [19] .
Spoligotyping is used to detect the 43 known spacer sequences that intersperse the directly repeated sequences in the genomic direct repeat region. The spoligotyping method, which has a lower level of discrimination than does IS6110 RFLP typing [20] , was used as an additional tool for determining relationships among the serial isolates. Altogether, 20 isolates (preferably 2 isolates from each patient, the first isolate and 1 of the serial isolates) were selected for spoligotyping. The procedure was performed according to standard protocols [16] .
RFLP profiles were analyzed by means of a computer program (Gelcompar, version 4.1; Applied Maths) by use of the Dice coefficient for similarity calculations and the unweighted pair-group method with arithmetic averages for clustering, as described elsewhere [21] . IS6110 RFLP fingerprinting and spoligotyping were done at the Swedish Institute for Infectious Disease Control in Stockholm.
Statistical analyses. Data analysis was performed by use of the SigmaStat program for Windows, version 2.0 (Jandel). Subject variables were examined by use of the x 2 test of association for categorical variables and the t test for continuous variables.
was considered to be statistically significant. P ! .05
RESULTS
Sociodemographic and clinical data. The 11 patients with TB could be divided into 2 groups. Group 1 included 6 patients with TB that was characterized by continuous excretion of drugsusceptible M. tuberculosis isolates for 110 months, despite anti-TB treatment. Group 2 included 5 patients with TB characterized by continuous excretion of M. tuberculosis isolates and a shift from susceptible to resistant strains (table 1). The majority of patients in both groups were male (5 of 6 in group 1 and 4 of 5 in group 2). The mean age was 47 years (range, 36-67 years) in group 1 and 43 years (range, 29-66 years) in group 2 (P p ). The majority of patients (all 6 patients in group 1 and 3 .5 patients in group 2) were alcohol abusers (
). In addition, P p .1 4 patients in group 1 and all 5 patients in group 2 were unemployed ( ). In both groups, 1 patient had previously P p .4 been imprisoned. With respect to the manifestation of TB and a history of TB, the patients in the 2 groups did not differ ( and , respectively) (table 2). P p .5 P p 1.0 Drug regimens, duration of therapy, and outcome for patients. Patients in both groups received initial daily therapy in hospitals. For group 1, the median duration of treatment was 45 days (range, 18-63 days); in group 2, it was 38 days (range, 28-52 days) ( ; table 2 ). The duration of the TB P p .3 episode varied from 19 to 60 months (mean, 37.4 months) for group 1 and from 14 to 66 months (mean, 42.9 months) for group 2 (
). There was no difference in the treatment P p .5 duration between the groups (range, 5.2-19.3 months, and median, 7.6 months for group 1; range, 3.0-36.9 months, and median, 24.5 months, for group 2; ) (table 3). P p .2 Treatment regimens were regularly changed in both groups. Therapy was changed 3-9 times (median, 4 changes) for patients in group 1 and 6-17 times (median, 7 changes) for patients in group 2 ( ). No standard regimens were applied P p .1 during the therapy. In both groups, the daily doses of drugs used in the treatment regimens were consistent with WHO recommendations (table 3) . The number of treatment interruptions of 12 months during the therapy was similar in both groups (range, 2-5 interruptions, and mean, 2.5 interruptions for patients in group 1; range, 2-5 interruptions, and mean, 3.2 interruptions for patients in group 2;
); a treatment P p .3 interruption of 12 months was considered to indicate poor compliance.
The treatment outcome did not differ statistically significantly between group 1 and group 2. Three patients in group 1 were cured, and 3 died. One patient in group 2 was cured, 3 patients died, and treatment was stopped for 1 patient because of a lack of active drugs remaining in the regimen (the isolate from that patient demonstrated resistance to 9 drugs). Bacterial isolates. The interval between the obtaining of samples for the first and the last isolate from each patient varied from 313 to 1201 days (mean, 828 days) for group 1 and from 370 to 1850 days (mean, 1091 days) for group 2 ( ) (figure P p .3 1). Twenty-six M. tuberculosis isolates obtained from 11 patients with TB were susceptible to rifampin, isoniazid, streptomycin, and ethambutol, and 8 M. tuberculosis isolates from 5 patients were MDR (i.e., resistant to at least isoniazid and rifampin) (table 1) .
Within group 1, 5 patients had a follow-up isolate with an IS6110 RFLP pattern that was identical to the pattern of the first isolate (figure 2). One patient had a second isolate with an RFLP pattern that slightly differed from that of the first isolate (1-band difference; loss of 1 band), whereas a third isolate from that patient was indistinguishable from the first. In group 2, 5 patients had follow-up isolates with RFLP patterns that clearly differed from the pattern of the first isolate, and, in 2 cases, the patterns of the first and second isolates differed from that of the third. In all such cases, these changes have been considered, after the possibility for laboratory crosscontamination was ruled out, to reflect the appearance of a new M. tuberculosis strain. In addition, 3 of the MDR M. tuberculosis isolates obtained from patients in group 2 (patients 1, 3, and 5) had the same RFLP pattern.
Twenty M. tuberculosis isolates were characterized by spoli- gotyping. In group 1, the spoligotypes of isolates obtained from the same patient did not vary during the study period. In all patients in group 2, the spoligotypes of the first and second isolates differed. All MDR M. tuberculosis isolates identified in group 2 had an identical spoligotype, one that belongs to the Beijing genotype [22] . The interval between the point at which the drug-susceptible M. tuberculosis isolates and the point at which MDR isolates were recovered from samples varied from 142 to 1364 days (mean, 617 days).
DISCUSSION
On the basis of our investigation of sequential isolates obtained from patients who experienced failure of treatment for active pulmonary TB, we propose that highly irregular treatment and unfavorable sociodemographic factors do not always lead to the emergence of drug resistance in drug-susceptible M. tuberculosis strains, even during a long treatment period. We have followed up 11 patients selected from patients in the ENRL TB register whose treatment failed during a 6-year period. The 11 patients were similar in most respects; they had similar sociodemographic status and met a full scale of preconditions, such as having had no standard regimens administered as therapy, having had no supervision of drug administration, and having exhibited poor treatment compliance. We found that 6 patients excreted isogenic drug-susceptible M. tuberculosis strains for 110 months. In contrast, in 5 patients, a strain shift occurred concurrently with the appearance of multidrug resistance. Treatment failure is defined by the WHO as the maintenance of or reversion to positive results of a smear and/or culture у5 months after the commencement of treatment in a patient receiving treatment or conversion from negative results before initiation of treatment to positive results of a smear and/or a culture after the second month of treatment [23] . Therefore, testing of specimens from patients with TB before initiation of treatment (sample 1) and at the end of the second (sample 2) and fifth (sample 3) months of treatment is recommended. We aimed to obtain at least 3 sequential isolates from the same TB episode from each patient and to maintain an interval between isolates of у2 months. In our TB laboratory register, during the 6-year period, there were 14 patients who fulfilled all inclusion criteria (i.e., initial diagnosis of TB caused by drugsusceptible organism, testing of at least 3 sequential isolates for drug susceptibility, and an interval between the isolates of у2 months). Out of all possible candidates, a clear majority (close to 80%) were recruited into our study.
In the present study, the standard and most widely applied Table 2 . Sociodemographic and clinical data for patients with tuberculosis (TB) who met the study inclusion criteria.
Group, patient
Age, years/sex Risk factor for TB infection molecular technique for distinguishing between strains in the M. tuberculosis complex, IS6110 RFLP typing, which has a high degree of discrimination and stability [20] , was used. The most unexpected result was that exogenous reinfection with a new M. tuberculosis strain during the same TB episode took place in 5 patients. By combining RFLP with spoligotyping, it was possible to classify these M. tuberculosis complex isolates as having the Beijing genotype. Although the spread of a drugresistant Beijing clone has been followed in wide, communitybased studies [24] , to the best of our knowledge, a causative association with clinical treatment regimens and failure of such regimens has not been demonstrated. Different studies have indicated that exogenous reinfection may occur after successful treatment [25] [26] [27] . However, limited data are available with regard to the rate at which superinfection will occur during the same episode of TB. Niemann et al. [28] have described a patient with TB who had double infection with a drug-resistant strain and an MDR strain. In our study, exogenous reinfection with the Beijing family of MDR M. tuberculosis was found in 5 immunocompetent patients with pulmonary TB. In addition, in all these cases, the physicians considered the emergence of drug resistance to be a result of unsupervised drug administration, poor patient compliance with therapy, and errors in medical prescriptions of drug regimens. It was demonstrated by molecular techniques that this was not the case.
Treatment of patients with TB who are infected with drugsusceptible M. tuberculosis strains has been successful. According to Mitchison and Nunn [29] , treatment failures among patients who were infected initially with drug-susceptible bacilli are rare among patients who have been treated with regimens of у3 drugs that include rifampin. In contrast to those findings, our study has demonstrated that viable organisms can persist (as demonstrated by culture positivity during therapy) in sputum for several months or years, despite the demonstration of drug susceptibility in vitro and administration of appropriate doses of drugs for chemotherapy. However, this persistence was associated with marked irregularity of TB therapy.
Mitchison [30] has described the emergence of drug resistance during short-course chemotherapy with multiple drugs, solely due to irregularity in administration of drugs, because of the occurrence of several cycles of killing (when the drugs are taken) and regrowth (when drug-taking stops). During each of these cycles, selection of mutants that are resistant, relative to the susceptible bacterial population, is possible. However, the drug-susceptible M. tuberculosis strains obtained from 6 patients in our study did not develop resistance, despite administration of highly irregular therapy. This might be the result of longer intervals during which the treatment was stopped; thereafter, during the regrowth period, the proportion of susceptible bacilli could quickly increase again.
Our findings show that highly irregular treatment and unfavorable sociodemographic factors do not always contribute to the emergence of drug resistance in drug-susceptible M. tuberculosis, despite a long treatment period. Regardless, the host did not benefit from the drug susceptibility of infecting M. tuberculosis; one-half of our patients died.
The detection of superinfection with a new M. tuberculosis strain during the treatment of an episode of active TB is possible only through the use of molecular epidemiology tools. The results obtained by use of these tools make it clear that patients who are treated in 11 hospital setting can become infected with a new and more dangerous strain of M. tuberculosis if infectious patients are not isolated; on the other hand, it may also be that these particular strains are extremely virulent. This type of nosocomial spread of TB is obscured by the ability to diagnose TB earlier in the course of the disease, and, therefore, the extent of the problem remains largely unknown.
